NS1

NS1 Overview

English NameSrc homology phosphotyrosyl phosphatase 2Approved Drugs0
Drugs in Clinical Trials20Target SynonymProtein Tyrosine Phosphatase Non-Receptor Type 11,SHP-2,PTP2C,Protein-tyrosine phosphatase 2C,PTP-2C,PTP-1D,SH-PTP3,PTPN11,Protein-Tyrosine Phosphatase 1D,SH-PTP2,EC:3.1.3.48,Noonan Syndrome 1,EC 3.1.3.48,METCDS,SHPTP2,BPTP3,JMML,SHP2,CFC,NS1,Protein Tyrosine Phosphatase, Non-Receptor Type 11,Tyrosine-Protein Phosphatase Non-Receptor Type 11
Highest Development StagePhase 3 Clinical
English NameSrc homology phosphotyrosyl phosphatase 2
Target SynonymProtein Tyrosine Phosphatase Non-Receptor Type 11,SHP-2,PTP2C,Protein-tyrosine phosphatase 2C,PTP-2C,PTP-1D,SH-PTP3,PTPN11,Protein-Tyrosine Phosphatase 1D,SH-PTP2,EC:3.1.3.48,Noonan Syndrome 1,EC 3.1.3.48,METCDS,SHPTP2,BPTP3,JMML,SHP2,CFC,NS1,Protein Tyrosine Phosphatase, Non-Receptor Type 11,Tyrosine-Protein Phosphatase Non-Receptor Type 11
Approved Drugs0
Drugs in Clinical Trials20
Highest Development StagePhase 3 Clinical

Product Inquiry

NS1 Background

Zika virus (ZIKV) is a member of the virus family Flaviviridae and the genus Flavivirus, transmitted by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Zika Forest of Uganda, where the virus was first isolated in 1947. Zika virus is related to dengue, yellow fever, Japanese encephalitis, and West Nile viruses. The infection, known as Zika fever, often causes no or only mild symptoms, similar to a mild form of dengue fever. It is treated by rest. Since the 1950s, it has been known to occur within a narrow equatorial belt from Africa to Asia. As of 2016, the illness cannot be prevented by drugs or vaccines. As of February 2016, there is evidence that Zika fever in pregnant women is associated with abnormal brain development in their fetuses through mother-to-child transmission of the virus, which may result in miscarriage or microcephaly.

NS1 Synonyms

NS1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
JAB-3312JAB-3312Phase 3 ClinicalJacobio Pharmaceuticals Co LtdSolid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung
Details
JAB-3068JAB-3068Phase 2 ClinicalJacobio Pharmaceuticals Co Ltd, Abbvie IncSolid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Adenoid Cystic; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung
Details
VociprotafibRMC-4630; SAR-442720Phase 2 ClinicalSanofi, Revolution Medicines IncSolid tumours; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
Details
BatoprotafibTNO-155Phase 2 ClinicalNovartis Pharma AgSolid tumours; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma
Details
GH-21GH 21005; GH-21; HBI-2376Phase 2 ClinicalSuzhou GenHouse pharmaceutical Co LtdSolid tumours; Head and Neck Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
BR-790BR-790Phase 2 ClinicalJiangxi Qingfeng Pharmaceutical Industry Co LtdSolid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
BBP-398IACS-15509; BBP-398; IACS-13909; BMS-986466Phase 2 ClinicalBridgebio Pharma Inc, The University Of Texas MD Anderson Cancer CenterSolid tumours; Carcinoma, Non-Small-Cell Lung
Details
MigoprotafibRLY-1971; GDC-1971; RO-7517834; RG-6433Phase 1 ClinicalRelay Therapeutics IncSolid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
A-380A-380Phase 1 ClinicalShandong Kelun Phaemaceutical Co Ltd, Klus Pharma IncNeoplasms
Details
KYHY-2303KYHY2303; KYHY-2303Phase 1 ClinicalJiangsu Kanion Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of SciencesHematologic Neoplasms
Details
RG-001RG001; RG-001Phase 1 ClinicalShanghai Lingji Biological Technology Co LtdNeoplasms
Details
HS-336HS336; HS-336Phase 1 ClinicalZhejiang Hisun Pharmaceutical Co LtdSolid tumours
Details
HMPL-415S1HMPL-415S1Phase 1 ClinicalHutchison Medipharma LtdSolid tumours
Details
BPI-442096Phase 1 ClinicalBetta Pharmaceuticals Co LtdSolid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
HS-10381HS-10381Phase 1 ClinicalJiangsu Hansoh Pharmaceutical Group Co LtdSolid tumours
Details
ET-0038ET-0038Phase 1 ClinicalShanghai Yituo Pharmaceutical Technology Co LtdSolid tumours
Details
PF-07284892ARRY-558; PF-07284892Phase 1 ClinicalPfizer IncSolid tumours; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung
Details
ICP-189ICP-189Phase 1 ClinicalInnoCare Pharma LtdSolid tumours; Carcinoma, Non-Small-Cell Lung
Details
ERAS-601ERAS-601Phase 1 ClinicalErasca IncSolid tumours; Leukemia, Myeloid, Acute
Details
SH-3809SH3809Phase 1 ClinicalNanjing Sanhome Pharmaceutical Co Ltd Solid tumours
Details
  • Overview
  • Product Inquiry
  • Clinical Drug Information
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8